Caris Life Sciences, a molecular science and technology company, entered into a strategic research partnership with Incyte Corp. to augment precision medicine approaches for Incyte’s oncology pipeline. Caris’ platform combines data from whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures to improve patient outcomes through advancement of personalized medicine. According to the company, the partnership will apply Caris’ da...